Almirall and BSC: A New Era in Dermatological Research
In a significant move to enhance medical dermatology, Almirall, a global biopharmaceutical company, has announced an expanded collaboration with the Barcelona Supercomputing Center (BSC). This strategic framework agreement aims to leverage cutting-edge technologies like Artificial Intelligence (AI) and High-Performance Computing (HPC) to identify new opportunities for developing therapies for skin diseases.
Strengthening Long-Standing Partnerships
The collaboration builds on a history of successful joint research and development projects between Almirall and BSC. By deepening their partnership, both organizations are committed to pushing the boundaries of scientific innovation to better address the needs of patients suffering from various skin conditions. This alliance is not just a continuation of their relationship; it represents a significant step forward in their shared mission to transform dermatological care.
Joining the BSC Connects Program
As part of this enhanced collaboration, Almirall will join the ‘BSC Connects’ program. This initiative is designed to foster public-private collaboration, allowing companies to tap into BSC’s extensive scientific expertise and technological resources. By participating in this program, Almirall will gain access to personalized training, cutting-edge technologies, and tailored support for co-developing innovative R&D projects through 2026. This strategic move will enable Almirall to integrate disruptive technologies throughout its research and development pipeline, ultimately benefiting patients in need of advanced dermatological treatments.
Innovation Through Disruptive Technologies
The partnership is a cornerstone of Almirall’s innovation strategy, which focuses on utilizing advanced technologies to develop novel treatments. By combining the scientific talent of BSC with Almirall’s deep understanding of dermatology, the collaboration aims to tackle complex dermatological challenges. This synergy will facilitate the identification of innovative technologies with high-impact potential, ranging from genomics to digital twins and drug design.
Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall, emphasized the importance of this collaboration, stating, “Our passion for medical dermatology drives us to constantly seek innovative solutions that can make a real difference in patients’ lives.” He highlighted that the partnership with BSC is crucial for accelerating the development of the next generation of skin treatments.
The Role of BSC in Advancing Science
BSC is a leading international research center and a key player in the European supercomputing landscape. The center specializes in HPC and AI, providing essential infrastructure and services to scientists across Europe. The ‘BSC Connects’ initiative aims to create a vibrant ecosystem where industry and academia can collaborate to tackle complex challenges and drive technological advancement. Mateo Valero, Director of BSC, noted that this agreement exemplifies how supercomputing and AI can significantly impact public health.
BSC Connects: Bridging Science and Industry
The BSC Connects program is designed to accelerate knowledge transfer between science and industry. It offers companies access to BSC’s scientific expertise, technology, and supercomputing capabilities. This includes specialized training, the development of use cases, and opportunities for collaboration on European projects. The structured approach of the program spans from identifying technological challenges to evaluating and optimizing results, acting as a bridge between BSC’s scientific talent and the broader innovation ecosystem.
About BSC and Almirall
BSC is one of Europe’s leading supercomputing centers, hosting one of the world’s most powerful supercomputers, MareNostrum 5. Its research focuses on various fields, including life sciences and computational social sciences. The center is supported by the Spanish government and the Generalitat de Catalunya, ensuring a robust framework for scientific inquiry.
Almirall, founded in 1944 and headquartered in Barcelona, is dedicated to medical dermatology. The company collaborates closely with scientists, healthcare professionals, and patients to deliver innovative solutions that improve lives. With a global presence in over 100 countries, Almirall is committed to transforming the dermatological landscape through groundbreaking research and development.
This collaboration between Almirall and BSC marks a pivotal moment in the quest for innovative dermatological therapies, showcasing the power of strategic partnerships in advancing healthcare.
